

Ref: EPL/CS/SE/0007/2024

Date: August 13, 2024

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Revision in Credit Rating


Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that CRISIL Ratings Limited ("CRISIL"), has upgraded its ratings on the bank loan facilities of Emcure Pharmaceuticals Limited, as under:

Facilities	Amount (Rs. in Crores)	Type of Rating	Rating	Rating Action
Bank Loan Facilities	2,475.43	Long Term Rating	CRISIL AA-/ Stable	Upgraded from 'CRISIL A+/Stable'
		Short Term Rating	CRISIL A1+	Upgraded from 'CRISIL A1'

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited



Chetan Sharma

Company Secretary & Compliance Officer

**Emcure Pharmaceuticals Limited****Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251